The product is indicated for the treatment of chronic hepatitis C, a blood-borne infectious disease that affects more than 100 million people in the developing world, including approximately 12 million people in India.
A startup company that’s found a unique niche in the exploding cannabis industry, Potbotics uses...
CBRE Group, Inc. announced today that they have been hired to sell Eli Lilly’s biomanufacturing...
Applied Genetic Technologies Corporation and 4D Molecular Therapeutics, leaders in next-...
Catalent Pharma Solutions announced the opening of a large scale expansion at its Winchester, KY, manufacturing facility.
The global treatment market for Duchenne Muscular Dystrophy (DMD) will expand in value at a staggering Compound Annual Growth Rate (CAGR) of 160.5%, from approximately $8.2 million in 2014 to $990 million by 2019, says research and consulting firm GlobalData.
$2.0 million of preferred stock will be purchased upon Synthonics’ achievement of certain milestones, which could be expected during 2016.
GE Healthcare Life Sciences and Rentschler Biotechnologie GmbH announced the expansion of Rentschler’s biopharmaceutical manufacturing capabilities.
Neothetics initiated Phase 3 trials of a non-invasive injectable for reduction of central abdominal bulging due to subcutaneous fat.
Merck is introducing Clinical Diabetes management for more than 5000 medical students in 18 medical colleges of Maharashtra University as part of Merck Capacity Advancement Program (CAP) in Asia.
Watson-Marlow Fluid Technology Group strengthens its biopharmaceutical offering through the acquisition of ASEPCO Corporation (Asepco).
Merck's agreement with AIAC is to sell the manufacturing facility in Arecibo that was under closing plans. AIAC will retain the approximately 200 Merck employees.
Biopharmaceutical research companies are currently developing more than 240 medicines for leukemia, lymphoma, myeloma and other forms of blood cancer.
Bristol-Myers Squibb has announced that it has completed its acquisition of Flexus Biosciences, Inc.
Phoenix has developed a novel family of New Molecular Entity (NME) opioids that appear to be non-addicting and free of all significant dangerous side effects.
Just as calibration needs to be part of your quality processes, it absolutely needs to be part of your asset performance management (APM) strategy as well.
Sampson and his three partners in Chicago-based Cresco Labs are switching livelihoods and risking millions of dollars to follow the promise of medical marijuana.
Valeant Pharmaceuticals International today announced it has completed the previously announced acquisition of Salix Pharmaceuticals.
HHS awarded approximately $12 million today to BioCryst Pharmaceuticals of Durham, North Carolina, for the advanced development of a promising experimental drug for Ebola, including preparing for large-scale manufacturing of the drug and conducting related studies.
Teva announces the launch of the generic equivalent to Exforge (amlodipine and valsartan) Tablets in four different strengths, in the United States.
Recipharm AB and Adroit Science AB have announced the formation of a new strategic collaboration. Adroit Science AB will support Recipharm’s pharmaceutical development with high quality solid state characterization services
Genentech, a member of the Roche Group, has announced plans to invest more than $125 million for the expansion of its fill/finish facility in Hillsboro, Oregon.
The goal of the collaboration is to discover and develop novel therapies to treat rare diseases with high unmet medical need combining Shire's development and commercialization capabilities with Cincinnati Children's research expertise.
Capsugel has announced that the company is investing more than $25 million to increase production capacity and deliver further quality enhancements for its vegetarian capsules.
AstraZeneca has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.
There are many nuances that require a more focused approach to risk identification and project management for the “new” manufacturing facilities implementing Single-use Systems (SUS).
Sun Pharma today, begins the integration of Ranbaxy's business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth.
Pfizer and Eli Lilly announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.
Coronado Biosciences has announced the formation of a new company, Mustang Therapeutics, Inc. Mustang will initially focus on the preclinical and clinical development, as well as commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology.
- Page 1